Our Take
Patent allowance is routine IP work; the real test is whether Acclaim-3 Phase II hits its 18-week progression-free survival target in 50 SCLC patients, not yet enrolled.
Why it matters
Gene therapy combinations with checkpoint inhibitors remain experimental. Genprex's ability to show tolerability in Phase I and now expand global IP coverage signals the company is moving forward, but efficacy data is 12-18 months away at minimum.
Do this week
Biotech investors: flag Acclaim-3's interim readout (after 25 patients complete 18 weeks) as the decision point for Reqorsa credibility; monitor for FDA feedback on the fast-track designation.
Patent allowance clears regulatory path, but trial enrollment matters more
Genprex received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for patent coverage of Reqorsa, a gene therapy, in combination with PD-1 or PD-L1 antibodies for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The patent complements existing protection in China, Europe, Japan, Russia, and the US.
The company is running Acclaim-3, a Phase I/II clinical trial combining Reqorsa with Genentech's Tecentriq (atezolizumab). The Phase I portion has been completed, with Reqorsa described as generally well tolerated (company-reported). Phase II will enroll nearly 50 patients with extensive-stage SCLC who have already received first-line Tecentriq and chemotherapy. The trial's primary endpoint is the 18-week progression-free survival rate following maintenance therapy with Reqorsa and Tecentriq combined. An interim analysis is scheduled after 25 patients complete 18 weeks of follow-up. The FDA granted both fast-track and orphan drug designations to the program.
In November 2024, Genprex licensed Reqorsa from the University of Michigan, expanding its broader oncology and diabetes pipeline built on non-viral, lipid-based nanoparticle delivery technology.
IP breadth signals commitment, but efficacy remains unproven
Patent allowances are standard defensive moves in pharma and do not indicate clinical progress. The allowance itself is not a clinical achievement; it is confirmation that CIPO found Genprex's claim to combining gene therapy with existing immunotherapies novel enough to protect across jurisdictions.
The real question is whether Acclaim-3 Phase II demonstrates that adding Reqorsa to an approved checkpoint inhibitor improves outcomes in SCLC patients. Small cell lung cancer has limited treatment options, and the orphan designation reflects that unmet need. However, the trial is still enrolling. Interim data after 25 patients will provide the first signal of whether the combination works; final Phase II results could take another year or more.
Patent coverage in multiple countries reduces the risk of competitors copying the approach once approved, but approval itself is not certain. Many Phase II trials fail or show marginal benefit.
Track the interim readout as the credibility checkpoint
Investors and clinical development teams should monitor the Acclaim-3 interim analysis (expected when the first 25 patients complete 18 weeks of follow-up) as the inflection point. Positive interim data would validate both the safety profile observed in Phase I and early signs of efficacy, strengthening the case for Phase III and supporting the company's IP strategy. Flat or negative interim results would raise questions about whether the combination offers sufficient benefit to justify further development. Patent breadth matters only if the drug works.